Trial
NCT02155634
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Multiple Myeloma
Intervention
Lenalidomide
Why stopped
The study was terminated due to poor feasibility and lack of interest at the participating sites.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-10